Inventiva S.A. (IVA)

NASDAQ: IVA · Real-Time Price · USD
6.53
+0.23 (3.65%)
At close: Oct 3, 2025, 4:00 PM EDT
6.01
-0.52 (-7.96%)
Pre-market: Oct 6, 2025, 8:45 AM EDT
3.65%
Market Cap872.66M
Revenue (ttm)19.93M
Net Income (ttm)-365.31M
Shares Out 139.15M
EPS (ttm)-4.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume113,125
Open6.34
Previous Close6.30
Day's Range6.26 - 6.55
52-Week Range1.60 - 6.55
Beta0.75
AnalystsStrong Buy
Price Target16.00 (+145.02%)
Earnings DateSep 29, 2025

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 118
Stock Exchange NASDAQ
Ticker Symbol IVA
Full Company Profile

Financial Performance

In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 7 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 145.02% from the latest price.

Price Target
$16.0
(145.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...

5 days ago - GlobeNewsWire

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.

Other symbols: MLTX
7 days ago - Benzinga

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...

7 days ago - GlobeNewsWire

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept.

7 days ago - Benzinga

Inventiva to Host Analyst and Investor Event on October 8, 2025

Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...

11 days ago - GlobeNewsWire

Inventiva to Participate in Upcoming September Investor Conferences

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...

4 weeks ago - GlobeNewsWire

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...

7 weeks ago - GlobeNewsWire

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the ...

2 months ago - GlobeNewsWire

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

3 months ago - GlobeNewsWire

Inventiva receives $10 million milestone payment from CTTQ

Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

3 months ago - GlobeNewsWire

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

3 months ago - GlobeNewsWire

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

4 months ago - GlobeNewsWire

Inventiva reports 2025 First Quarter Financial Information¹

Daix (France),  New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...

4 months ago - GlobeNewsWire

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development...

4 months ago - GlobeNewsWire

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t...

5 months ago - GlobeNewsWire

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

5 months ago - GlobeNewsWire

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis

5 months ago - GlobeNewsWire

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Daix (France),  New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...

6 months ago - GlobeNewsWire

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...

6 months ago - GlobeNewsWire

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Inventiva S.A. (NASDAQ:IVA) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified ...

6 months ago - Seeking Alpha

Inventiva reports its 2024 full year results and provides a business update

Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...

6 months ago - GlobeNewsWire

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused o...

7 months ago - GlobeNewsWire

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...

7 months ago - GlobeNewsWire

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Daix (France), New York City (New York, United States), Tokyo (Japan), February 20,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutica...

8 months ago - GlobeNewsWire

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develo...

8 months ago - GlobeNewsWire